What is Deepcell?
Deepcell is at the forefront of precision medicine, leveraging a unique combination of artificial intelligence, advanced cell classification, and single-cell capture technology. Founded in 2017, the company has developed proprietary microfluidics-based technology powered by continuously learning AI. This platform enables unbiased cell classification based on detailed visual features and precise sorting, maintaining cell viability for subsequent analysis. Deepcell's technology is capable of isolating rare cell types, even those present at frequencies as low as one in a billion, offering unprecedented insights into cell biology. Initially offered as a service, the platform supports translational research, diagnostics, and therapeutic development.
How much funding has Deepcell raised?
Deepcell has raised a total of $93M across 2 funding rounds:
Series A
$20M
Series B
$73M
Series A (2020): $20M with participation from Andreessen Horowitz, Jeff Dean, Stanford University, 50Y, Bow Capital, and DCVC
Series B (2022): $73M led by Horizons Ventures, Casdin Capital, Koch Disruptive Technologies, and Bridger Healthcare
Key Investors in Deepcell
Andreessen Horowitz
Andreessen Horowitz is a prominent venture capital firm known for investing in technology companies across various stages. Their focus often includes software, internet, and emerging technologies, providing strategic guidance and capital to foster innovation and growth.
DCVC
DCVC is a venture capital firm specializing in deep technology, investing in companies that leverage artificial intelligence and other advanced technologies to solve complex global challenges. They support ambitious founders in sectors like biotechnology and energy.
Casdin Capital
Casdin Capital is a venture capital firm with a strong focus on life sciences innovation, particularly in diagnostics and molecular information. They invest in pioneering companies and provide strategic support to advance healthcare technologies.
What's next for Deepcell?
The substantial enterprise-level funding and recent strategic investment position Deepcell for accelerated growth and market expansion. With its Series B financing, the company is poised to further develop and scale its AI-powered cell analysis platform. This capital infusion will likely fuel advancements in its service offerings for translational research and diagnostics, as well as bolster its efforts in therapeutic development. Deepcell's trajectory suggests a move towards broader commercialization and deeper integration into the precision medicine ecosystem, potentially solidifying its role as a key player in unlocking novel biological insights.
See full Deepcell company page
